vs
ARTIVION, INC.（AORT）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
BRC Group Holdings, Inc.的季度营收约是ARTIVION, INC.的1.6倍（$188.3M vs $116.0M），BRC Group Holdings, Inc.净利率更高（47.9% vs 2.1%，领先45.9%），ARTIVION, INC.同比增速更快（19.2% vs -21.9%），过去两年ARTIVION, INC.的营收复合增速更高（9.1% vs -15.4%）
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
AORT vs RILY — 直观对比
营收规模更大
RILY
是对方的1.6倍
$116.0M
营收增速更快
AORT
高出41.1%
-21.9%
净利率更高
RILY
高出45.9%
2.1%
两年增速更快
AORT
近两年复合增速
-15.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $116.0M | $188.3M |
| 净利润 | $2.4M | $90.3M |
| 毛利率 | 63.1% | 79.5% |
| 营业利润率 | 9.2% | 32.3% |
| 净利率 | 2.1% | 47.9% |
| 营收同比 | 19.2% | -21.9% |
| 净利润同比 | 114.7% | 1710.8% |
| 每股收益（稀释后） | $0.06 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AORTRILY
| Q4 25 | $116.0M | $188.3M | ||
| Q3 25 | $113.4M | $215.3M | ||
| Q2 25 | $113.0M | $188.2M | ||
| Q1 25 | $99.0M | $197.2M | ||
| Q4 24 | $97.3M | $241.0M | ||
| Q3 24 | $95.8M | $225.5M | ||
| Q2 24 | $98.0M | $256.0M | ||
| Q1 24 | $97.4M | $263.4M |
净利润AORTRILY
| Q4 25 | $2.4M | $90.3M | ||
| Q3 25 | $6.5M | $91.1M | ||
| Q2 25 | $1.3M | $139.5M | ||
| Q1 25 | $-505.0K | $-10.0M | ||
| Q4 24 | $-16.5M | $-5.6M | ||
| Q3 24 | $-2.3M | $-284.4M | ||
| Q2 24 | $-2.1M | $-433.6M | ||
| Q1 24 | $7.5M | $-49.2M |
毛利率AORTRILY
| Q4 25 | 63.1% | 79.5% | ||
| Q3 25 | 65.6% | 83.7% | ||
| Q2 25 | 64.7% | 81.3% | ||
| Q1 25 | 64.2% | 81.4% | ||
| Q4 24 | 63.2% | 79.8% | ||
| Q3 24 | 63.7% | 82.1% | ||
| Q2 24 | 64.6% | 84.5% | ||
| Q1 24 | 64.6% | 85.3% |
营业利润率AORTRILY
| Q4 25 | 9.2% | 32.3% | ||
| Q3 25 | 11.1% | 30.4% | ||
| Q2 25 | 7.4% | 5.7% | ||
| Q1 25 | 2.2% | -31.2% | ||
| Q4 24 | 2.7% | -69.2% | ||
| Q3 24 | 4.6% | -36.4% | ||
| Q2 24 | 6.6% | -90.8% | ||
| Q1 24 | 26.0% | -6.1% |
净利率AORTRILY
| Q4 25 | 2.1% | 47.9% | ||
| Q3 25 | 5.7% | 42.3% | ||
| Q2 25 | 1.2% | 74.1% | ||
| Q1 25 | -0.5% | -5.1% | ||
| Q4 24 | -16.9% | -2.3% | ||
| Q3 24 | -2.4% | -126.1% | ||
| Q2 24 | -2.2% | -169.4% | ||
| Q1 24 | 7.7% | -18.7% |
每股收益（稀释后）AORTRILY
| Q4 25 | $0.06 | $2.78 | ||
| Q3 25 | $0.13 | $2.91 | ||
| Q2 25 | $0.03 | $4.50 | ||
| Q1 25 | $-0.01 | $-0.39 | ||
| Q4 24 | $-0.40 | $-0.01 | ||
| Q3 24 | $-0.05 | $-9.39 | ||
| Q2 24 | $-0.05 | $-14.35 | ||
| Q1 24 | $0.18 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.9M | $226.6M |
| 总债务越低越好 | $215.1M | $1.4B |
| 股东权益账面价值 | $448.2M | $-171.5M |
| 总资产 | $884.8M | $1.7B |
| 负债/权益比越低杠杆越低 | 0.48× | — |
8季度趋势，按日历期对齐
现金及短期投资AORTRILY
| Q4 25 | $64.9M | $226.6M | ||
| Q3 25 | $73.4M | $184.2M | ||
| Q2 25 | $53.5M | $267.4M | ||
| Q1 25 | $37.7M | $138.3M | ||
| Q4 24 | $53.5M | $146.9M | ||
| Q3 24 | $56.2M | $159.2M | ||
| Q2 24 | $55.0M | $236.9M | ||
| Q1 24 | $51.1M | $190.7M |
总债务AORTRILY
| Q4 25 | $215.1M | $1.4B | ||
| Q3 25 | $214.9M | $1.3B | ||
| Q2 25 | $215.6M | $1.3B | ||
| Q1 25 | $314.7M | $1.4B | ||
| Q4 24 | $314.3M | $1.5B | ||
| Q3 24 | $314.0M | — | ||
| Q2 24 | $313.6M | — | ||
| Q1 24 | $313.3M | — |
股东权益AORTRILY
| Q4 25 | $448.2M | $-171.5M | ||
| Q3 25 | $438.7M | $-260.5M | ||
| Q2 25 | $419.9M | $-351.7M | ||
| Q1 25 | $294.3M | $-496.8M | ||
| Q4 24 | $276.2M | $-488.2M | ||
| Q3 24 | $304.7M | $-497.6M | ||
| Q2 24 | $295.1M | $-218.3M | ||
| Q1 24 | $295.0M | $228.4M |
总资产AORTRILY
| Q4 25 | $884.8M | $1.7B | ||
| Q3 25 | $857.7M | $1.7B | ||
| Q2 25 | $838.4M | $1.5B | ||
| Q1 25 | $791.2M | $1.5B | ||
| Q4 24 | $789.1M | $1.8B | ||
| Q3 24 | $803.1M | $2.2B | ||
| Q2 24 | $789.5M | $3.2B | ||
| Q1 24 | $784.0M | $5.0B |
负债/权益比AORTRILY
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 1.14× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.06× | — | ||
| Q1 24 | 1.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.6M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $-7.9M | — |
| 自由现金流率自由现金流/营收 | -6.9% | — |
| 资本支出强度资本支出/营收 | 23.7% | — |
| 现金转化率经营现金流/净利润 | 8.06× | 0.29× |
| 过去12个月自由现金流最近4个季度 | $839.0K | — |
8季度趋势，按日历期对齐
经营现金流AORTRILY
| Q4 25 | $19.6M | $26.2M | ||
| Q3 25 | $22.3M | $-60.6M | ||
| Q2 25 | $15.0M | $-25.6M | ||
| Q1 25 | $-17.0M | $184.0K | ||
| Q4 24 | $10.1M | $-2.7M | ||
| Q3 24 | $11.5M | $19.5M | ||
| Q2 24 | $6.1M | $111.5M | ||
| Q1 24 | $-5.5M | $135.4M |
自由现金流AORTRILY
| Q4 25 | $-7.9M | — | ||
| Q3 25 | $17.7M | — | ||
| Q2 25 | $11.7M | — | ||
| Q1 25 | $-20.6M | — | ||
| Q4 24 | $8.7M | — | ||
| Q3 24 | $7.8M | — | ||
| Q2 24 | $3.6M | — | ||
| Q1 24 | $-9.1M | — |
自由现金流率AORTRILY
| Q4 25 | -6.9% | — | ||
| Q3 25 | 15.6% | — | ||
| Q2 25 | 10.4% | — | ||
| Q1 25 | -20.8% | — | ||
| Q4 24 | 9.0% | — | ||
| Q3 24 | 8.2% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | -9.3% | — |
资本支出强度AORTRILY
| Q4 25 | 23.7% | — | ||
| Q3 25 | 4.1% | — | ||
| Q2 25 | 2.9% | — | ||
| Q1 25 | 3.7% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | 2.6% | — | ||
| Q1 24 | 3.7% | — |
现金转化率AORTRILY
| Q4 25 | 8.06× | 0.29× | ||
| Q3 25 | 3.42× | -0.66× | ||
| Q2 25 | 11.16× | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.73× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
